Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice
https://doi.org/10.17650/2222-8721-2025-15-1-53-60
Abstract
Background. Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a variant in the DMD gene, leading to severe disability and death at a young age. Today, in some variants in the DMD gene, etiopathogenetic therapy is possible to increase the patient’s life expectancy and improve his quality of life.
Aim. To evaluate the dynamics of assess the dynamics of the ability to walk independently in patients with DMD caused by a nonsense variant in the DMD gene on the background of therapy with the drug ataluren.
Materials and methods. The study included 9 patients with DMD caused by nonsense variants in the DMD gene. Of them, 3 patients were brothers and lost the ability to walk, 6 patients at the ambulatory stage of the disease received therapy with the drug ataluren according to the standard scheme. The six-minute walk test was chosen as the main parameter to assess the treatment efficacy in comparison with the baseline values before treatment.
Results. According to the data of six-minute walk test during the observation period 5 patients taking ataluren during 18–36 months retained the ability to move independently. One patient who initially walked 12 m lost ambulation 6 months after starting ataluren therapy. Compared with 3 non-ambulatory brothers with DMD due to the DMD nonsense gene variant who did not receive ataluren, 3 younger brothers on ataluren therapy retained ambulation at an age when the older brothers had already become non-ambulatory.
Conclusion. Pathogenetic therapy with the drug ataluren slows down the clinical course of DMD caused by a nonsense variant in the DMD gene with preservation of ambulatory capacity and is characterized by good tolerability.
About the Authors
D. V. Aizatulina
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
Build. 1, 18 Kremlevskaya St., Kazan 420008
S. S. Nikitin
Research Centre for Medical Genetics
Russian Federation
Russian Federation
1 Moskvorechye St., Moscow 115522
References
1. WHO motor development study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl 2006;450:86–95. DOI: 10.1080/08035320500495563
2. Birnkrant D.J., Busby K., Bann C.M. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17(3):251–67. DOI: 10.1016/S1474-4422(18)30024-3
3. Bushby K., Finkel R., Birnkrant D.J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93. DOI: 10.1016/S1474-4422(09)70271-6
4. Emery A.E.H., Muntoni F., Quinlivan R. Duchenne Muscular Dystrophy. 4th edn. Oxford: Oxford University Press, 2015.
5. Gremyakova T.A., Artemyeva S.B., Vashakmadze N.D. et al. The concept of “ambulatory“ and “non-ambulatory” in patients with Duchenne muscular dystrophy: definitions and criteria. Nervno-myshechnye bolezni = Neuromuscular Diseases 2021;12(1):10–8. (In Russ.). DOI: 10.17650/2222-8721-2022-12-2-10-18
6. Haber G., Conway K., Paramsothy P. et al. Association of genetic mutations and loss of ambulation in childhood-onset dystrophinopathy. Muscle Nerve 2021;63(2):181–91. DOI: 10.1002/mus.27113
7. Anisimova I.V., Artemyeva S.B., Belousova E.D. et al. Duchenne muscular dystrophy: modern approaches in patient management. Pediatricheskaya farmakologiya = Pediatric Pharmacology 2023;20(5):427–53. (In Russ.). DOI: 10.15690/pf.v20i5.2615
8. Gloss D., Moxley R.T., Ashwal S. et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy – report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(5):465–72. DOI: 10.1212/WNL
9. Moxley R.T., Ashwal S., Pandya S. et al. Practice parameter: Corticosteroid treatment of Duchenne dystrophy – report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13–20. DOI: 10.1212/01.WNL.0000148485.00049
10. McDonald C.M., Fowler W.M.Jr. The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease. Phys Med Rehabil Clin N Am 2012;23:475–93.
11. Bushby K., Finkel R., Birnkrant D.J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: Implementation of multidisciplinary care. Lancet Neurol 2010;9:177–89.
12. Gao Q.Q., McNally E.M. The dystrophin complex: Structure, function, and implications for therapy. Compr Physiol 2015;5(3):1223–39. DOI: 1002/cphy.c140048
13. Zinina E.V., Bulakh M.V., Ryzhkova O.P. et al. Change in the spectrum of detected mutations in the DMD gene depending on the methodological capabilities of the laboratory. Nervnomyshechnye bolezni = Neuromuscular Diseases 2023;13(1):33–43. (In Russ.). DOI: 10.17650/2222-8721-2023-13-1-33-43
14. Welch E.M., Barton E.R., Zhuo J. et al. PTC124 targets genetic disorders caused by sense mutations. Nature 2007;447(7140):87– 91. DOI: 10.1038/nature05756
15. EMA SMH. Translarna, INN – ataluren. Available at: https://www.ema.europa.eu/en/documents/overview/translarna-epar-medicineoverview_en.pdf.
16. McDonald C.M., Henricson E.K., Abresch R.T. et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013;48(3):357–68. DOI: 1002/mus.23905
17. Mazzone E., Martinelli D., Berardinelli A. et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712–6. DOI: 10.1016/j.nmd.2010.06.014
18. Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3 placebo-controlled trial. 27th International Annual Congress of the World Muscle Society, Halifax, 2022.
19. Ataluren preserves motor function in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial. Muscular Dystrophy Association Clinical and Scientific Conference, Dallas, 2023.
20. Weber F.J., Latshang T.D., Blum M.R. et al. Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta-analysis. Muscle Nerve 2022;66(4):462–70. DOI: 1002/mus.27682
21. Popovich S.G., Kuzenkova L.M., Uvakina E.V. et al. The use of the drug ataluren for the treatment of patients with Duchenne muscular dystrophy in real clinical practice. Nevrologicheskiy zhurnal im. L.O. Badalyana = L.O. Badalyan Neurological Journal 2024;5(2):79–89. (In Russ.). DOI: 10.46563/2686-8997-2024-5-2-79-89
Review
For citations:
Aizatulina D.V., Nikitin S.S. Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice. Neuromuscular Diseases. 2025;15(1):53-60. (In Russ.) https://doi.org/10.17650/2222-8721-2025-15-1-53-60
Views:
113
Email this article 